Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Anti-PD-L1 antibodies / PD-L1 inhibitors & Cigarette Smoking / Tobacco Smoking

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Studies have consistently shown that PD-1/PD-L1 inhibitors are more effective in patients with a history of smoking compared to non-smokers
Li et al. 2018h Onco Targets Ther. 11: 3691-3696
Norum & Nieder 2018 ESMO Open. 3(6): e000406

…

References (Sources)

Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis
Li et al. 2018h Onco Targets Ther. 11: 3691-3696
Meta-Analysis
Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis
Nie et al. 2020 Immunotherapy 12: 1313–1324
Meta-Analysis
Review
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature
Norum & Nieder 2018 ESMO Open. 3(6): e000406

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Anti-PD-L1 antibodies / PD-L1 inhibitors & Cigarette Smoking / Tobacco Smoking

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat